Drug pricing is a major policy issue in the US with both Congress and the Trump Administration offering proposals for reform, but state governments are also moving forward with their…
A recent analysis from Clarivate Analytics’ Cortellis identifies 11 drugs that are expected to enter the market in 2020 and achieve blockbuster status by 2024. Which drugs are making the…
Orphan drugs, defined in the US as a drug to treat less than 200,000 patients, have accounted for more than 40% of new drug approvals by the FDA over the…
With five new molecular entities launched in 2019 and two potential blockbusters targeted for launch in 2020, is the strategy of Novartis CEO Vas Narasimhan to drive growth in the…
The number of parenteral drugs in the industry’s pipeline and recently approved new drugs continues to rise with the increase of biologics and more complex active pharmaceutical ingredients. DCAT Value…
FDA, FTC Join To Increase Biologic Drug Competition
The FDA and FTC are collaborating to advance market competition in biologics, including for biosimilars. What have the agencies done thus far and what are they planning to do? The…
Small molecules still lead over biologics in recent drug approvals, accounting for nearly three-fourths of drug approvals over the past several years, but will small molecules’ dominance continue? DCAT Value…
The UK officially withdrew from the European Union (EU) on January 31 and now has until the end of 2020 to negotiate a trade deal with the EU. How may…
2020 Vision: What is Impacting Global Supply Lines?
From a more pessimistic macroeconomic view, to uncertainty arising from ongoing trade conflicts, and geopolitical tensions, executives weigh in on key issues that will impact performance in 2020. Taking the…
The European Federation of Pharmaceutical Industries and Associations (EFPIA), which represents research-based innovator companies, put out a position paper on how to best address drug shortages. This follows reports by…
